Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioMS Medical Corp.
Multiple sclerosis drug developer reports loss of $0.05 per share
June 15th, 2005
BioMS Medical Corp. (MS), a developer in the treatment of multiple sclerosis (MS), announced results for the first quarter ended March 31, 2005. "During the quarter, we initiated patient dosing for our pivotal phase II/III multiple sclerosis trial for the treatment of secondary progressive MS. This trial now involves nine sites across Canada and we are on track to expand the trial into the United Kingdom and other jurisdictions in Europe," said Kevin Giese, president of BioMS Medical. "By raising more than $41 million in the quarter through a prospectus offering, we have ensured that we are well financed to advance this trial and also undertake a...
Source: Physician Law Weekly (2005-06-15)
|
